




# Next Generation Bioactive Coatings to Improve Vascular Medical Devices

## OVERVIEW

VasoBio is a biotech startup that has developed a bioactive coating technology to improve healthy healing and longevity of vascular medical devices a \$9.2 B market.

## BACKGROUND & TECHNOLOGY

In the US alone, 500 K cases of end-stage renal disease will require hemodialysis. Arteriovenous dialysis grafts are the current standard of care for hemodialysis vascular access. Yet **77% of these grafts fail in year one** and **96% fail by year two**, putting the patients at risk for repeated operations. This is primarily due to the grafts' lack of regenerative potential and functional endothelium. Limited progress has been made in this field for the last 3 decades and there is a significant unmet need for long-lasting vascular grafts.



Our innovative patented coating technology is based on a novel endothelial cell and endothelial progenitor cell capturing ligand. Vascular grafts coated with our technology mimic the body's native vascular system to promote endothelial cell and endothelial progenitor cell attachment and growth, which provides resistance to thrombosis, infection, and blood clotting.

**No other competing technology is structurally stable or functionally specific making our patented solution the best option for providers and patients.**

## OPPORTUNITY

We currently focus on the vascular graft market (valued at **\$1.2 B**) and will then expand into adjacent markets including stents (valued at **\$3.7 B**), and implantable ports (valued at **\$4.4 B**). We are interested in partner with established vascular graft corporations and intravascular device companies.

## FINANCING

VasoBio is seeking strategic partnerships and investment as we move our product to the market.

## AT A GLANCE

- [ Focus ] vascular medical devices
- [ Contact ] vasobiainfo@gmail.com
- [ Website ] vasobio.com
- [ Location ] Sacramento, CA

## MILESTONES

- [2021 Complete Large Animal Studies]  
Complete prototyping; Early safety Efficacy Pursue partnership with KidneyX Phase II
- [2022 GMP Production and Efficacy Study]  
Pursue partnership with NHLBI SMARTT
- [2024 Prepare to Go to Market]  
Complete 510(k) submission and approval

## EXECUTIVE TEAM

Aijun Wang, Cofounder

[co-inventor of the technology; over 15 years of experience in bioengineering and vascular device development]

Kit Lam, Cofounder

[co-inventor of the technology; over 30 years of experience in combinatorial chemistry and nanotechnology]

Alyssa Panitch, Cofounder

[a serial entrepreneur; over 20 years of experience in company management, regulatory path and FDA interactions]

Program	Application	Discovery	Proof of Concept	IND Enabling	Phase I
VasoGraft - Dialysis	Dialysis	██████████	██████████	██████████	
VasoGraft - Vascular	PTFE Grafts	██████████	██████████		
VasoStent	Stents	██████████	██████████		

## FINANCING

VasoBio is seeking strategic partnerships and investment as we move our product to the market.